Compare IXHL & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IXHL | ONMD |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 42.1M |
| IPO Year | 2024 | 2021 |
| Metric | IXHL | ONMD |
|---|---|---|
| Price | $3.52 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 80.0K | ★ 801.0K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.33 |
| EPS | N/A | ★ N/A |
| Revenue | $12,000.00 | ★ $1,359,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 111.35 |
| 52 Week Low | $0.16 | $0.49 |
| 52 Week High | $6.39 | $4.22 |
| Indicator | IXHL | ONMD |
|---|---|---|
| Relative Strength Index (RSI) | 64.69 | 41.81 |
| Support Level | $2.79 | $0.58 |
| Resistance Level | $3.68 | $0.85 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 100.00 | 12.29 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.